- Record: found
- Abstract: found
- Article: not found
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Simona Soverini
1 ,
Giovanni Martinelli ,
Gianantonio Rosti ,
Simona Bassi ,
Marilina Amabile ,
Angela Poerio ,
Barbara Giannini ,
Elena Trabacchi ,
Fausto Castagnetti ,
Nicoletta Testoni ,
Simona Luatti ,
Antonio de Vivo ,
Daniela Cilloni ,
Barbara Izzo ,
Milena Fava ,
Elisabetta Abruzzese ,
Daniele Alberti ,
Fabrizio Pane ,
Giuseppe Saglio ,
Michele Baccarani
Jun 20 2005
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with clinical resistance to imatinib mesylate in chronic myeloid leukemia (CML) patients. To shed further light on the frequency, distribution, and prognostic significance of ABL mutations, we retrospectively analyzed a homogeneous cohort of late chronic phase CML patients who showed primary cytogenetic resistance to imatinib.